Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (161-170 of 222) with videos related to

Pageof 23
Sort By:
Journal of Cutaneous Medicine and Surgery|November 11, 2015
Psoriasis and Smoking: A Systematic Literature Review and Meta-Analysis With Qualitative Analysis of Effect of Smoking on Psoriasis SeverityVincent Richer, Camille Roubille, Patrick Fleming, et al.
BMJ Open|November 28, 2020
International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationaleKatrina Abuabara, Jonathan I Silverberg, Eric L Simpson, et al.
Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD StudyJennifer Soung, Yong Cui, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|January 24, 2025
Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)Robert Bissonnette, Elena Goleva, Evgeny Berdyshev, et al.
Journal of the American Academy of Dermatology|November 28, 2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataBruce Strober, Craig Leonardi, Kim A Papp, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|April 2, 2021
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With AbrocitinibEric L Simpson, Andreas Wollenberg, Robert Bissonnette, et al.
The Journal of Allergy and Clinical Immunology|August 17, 2019
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trialRobert Bissonnette, Ana B Pavel, Aisleen Diaz, et al.
JAMA Dermatology|November 2, 2022
Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice GuidelinesSara Mirali, Evan Tang, Aaron M Drucker, et al.
Acta Dermato-Venereologica|April 21, 2023
The Treat-to-Target Project in Atopic Dermatitis: One Year OnMarjolein De Bruin-Weller, Mette Deleuran, Tilo Biedermann, et al.
Pageof 23

Showing results (161-170 of 222) with videos related to

Sort By:
Pageof 23
Journal of Cutaneous Medicine and Surgery|November 11, 2015
Psoriasis and Smoking: A Systematic Literature Review and Meta-Analysis With Qualitative Analysis of Effect of Smoking on Psoriasis SeverityVincent Richer, Camille Roubille, Patrick Fleming, et al.
BMJ Open|November 28, 2020
International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationaleKatrina Abuabara, Jonathan I Silverberg, Eric L Simpson, et al.
Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD StudyJennifer Soung, Yong Cui, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|January 24, 2025
Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)Robert Bissonnette, Elena Goleva, Evgeny Berdyshev, et al.
Journal of the American Academy of Dermatology|November 28, 2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataBruce Strober, Craig Leonardi, Kim A Papp, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|April 2, 2021
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With AbrocitinibEric L Simpson, Andreas Wollenberg, Robert Bissonnette, et al.
The Journal of Allergy and Clinical Immunology|August 17, 2019
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trialRobert Bissonnette, Ana B Pavel, Aisleen Diaz, et al.
JAMA Dermatology|November 2, 2022
Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice GuidelinesSara Mirali, Evan Tang, Aaron M Drucker, et al.
Acta Dermato-Venereologica|April 21, 2023
The Treat-to-Target Project in Atopic Dermatitis: One Year OnMarjolein De Bruin-Weller, Mette Deleuran, Tilo Biedermann, et al.
Pageof 23